Bolt Current Deferred Revenue from 2010 to 2024
| BOLT Stock | USD 0.63 0.01 1.56% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 2.2 M | Current Value 2 M | Quarterly Volatility 786 K |
Check Bolt Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bolt Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 6.5 M, Interest Income of 6.5 M or Depreciation And Amortization of 2.5 M, as well as many indicators such as Price To Sales Ratio of 5.11, Dividend Yield of 0.0 or PTB Ratio of 0.39. Bolt financial statements analysis is a perfect complement when working with Bolt Biotherapeutics Valuation or Volatility modules.
Bolt | Current Deferred Revenue |
Latest Bolt Biotherapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Bolt Biotherapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Bolt Biotherapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bolt Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Bolt Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 1,104,739 | |
| Geometric Mean | 905,775 | |
| Coefficient Of Variation | 71.15 | |
| Mean Deviation | 674,318 | |
| Median | 599,000 | |
| Standard Deviation | 786,016 | |
| Sample Variance | 617.8B | |
| Range | 2.3M | |
| R-Value | 0.78 | |
| Mean Square Error | 262.6B | |
| R-Squared | 0.61 | |
| Significance | 0.0006 | |
| Slope | 136,752 | |
| Total Sum of Squares | 8.6T |
Bolt Current Deferred Revenue History
About Bolt Biotherapeutics Financial Statements
Bolt Biotherapeutics shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Bolt Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Bolt Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bolt Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 2.2 M | 2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.